ClinicalTrials.gg

Program

gotistobart

Also written as “ONC-392”, “Gotistobart” and “ONC-392 low”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Prostatic Neoplasms, led by OncoC4.

Furthest: phase 3, since Dec 26, 20225 company-led studies, 5 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
OncoC455 open or runningphase 3since Dec 26, 2022Oct 24, 2019Nov 30, 2026phase 2 · NCT05682443

Also a collaborator on its studies: Merck and BioNTech.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04140526 · 733 enrolled · United States, Australia
  2. Jun 30, 2022Phase 2 study in Ovarian NeoplasmsNCT05446298 · 58 enrolled · United States
  3. Dec 26, 2022Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT05682443 · 148 enrolled · United States
  4. Dec 26, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05671510 · 630 enrolled · United States, Australia, Belgium and more
  5. Jun 15, 2026Phase 3 study in Advanced Solid TumorNCT07659379 · 20 planned · United States

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT05682443
  2. Dec 31, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04140526
  3. Aug 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05671510
  4. Jul 1, 2036Primary completion: phase 3 study in Advanced Solid TumorNCT07659379

TargetBeta

CTLA4 →read by rule
“A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), ”NCIt, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07659379Advanced Solid Tumor · United States3By invitationJul 1, 203620
NCT05682443Metastatic Castration-resistant Prostate Cancer · United States2Active, not recruitingNov 30, 2026148
NCT05671510Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingAug 31, 2027630
NCT05446298Ovarian Neoplasms · United States2Active, not recruitingAug 30, 202658
NCT04140526Carcinoma, Non-Small-Cell Lung · United States, Australia2Active, not recruitingDec 31, 2026733

How it is read

Names in the registry

  • “ONC-392”, 2 entries
  • “Gotistobart”, 2 entries
  • “ONC-392 low”, 1 entry
  • “ONC-392 high”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.